Disease block
C45-C49 – Bösartige Neubildungen des mesothelialen Gewebes und des Weichteilgewebes
- Chapter II: Neubildungen
19Decisions
22Patient groups
Added benefit by patient group
- Major1
- Considerable4
- Minor1
- Not proven16
Diseases in this disease block
- C45 Mesotheliom 7 decisions
- C46 Kaposi-Sarkom [Sarcoma idiopathicum multiplex haemorrhagicum] 5 decisions
- C47 Bösartige Neubildung der peripheren Nerven und des autonomen Nervensystems 5 decisions
- C48 Bösartige Neubildung des Retroperitoneums und des Peritoneums 16 decisions
- C49 Bösartige Neubildung sonstigen Bindegewebes und anderer Weichteilgewebe 6 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-07-16ElahereMirvetuximab SoravtansinConsiderable
- 2026-04-16AyvakytAvapritinibNot proven
- 2025-10-16KeytrudaPembrolizumabNot proven
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-06-06RubracaRucaparibNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-09-21RubracaRucaparibNot proven
- 2023-09-21LynparzaOlaparibNot proven
- 2023-04-20LynparzaOlaparibConsiderable
- 2022-06-16QinlockRipretinibMajor
- 2021-12-16OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-07-15ZejulaNiraparibNot proven
- 2021-05-20ZejulaNiraparibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-04-02VitrakviLarotrectinibNot proven
- 2018-12-06LynparzaOlaparibMinor
- 2016-12-01HalavenEribulinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-02-19StivargaRegorafenibNot proven
Data status: 2026-10-29